Sign inJoin waitlistJoin the waitlist

VD

Vu Duong

Associate Professor · Univ of Maryland Sch of Med

Credentials: · · · · ·

History

Univ of Maryland Sch of Med · University of Maryland Capital Region Health
Present

H. Lee Moffitt Cancer Center and Research Institute
2008–2011
Internal Medicine
University of Virginia Medical Center
2005–2008
Clinical and Translational Research, University of South Florida
University of Virginia School of Medicine
2001–2005
Biomedical Engineering, Virginia Commonwealth University
1997–2001

Research

TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases
Cancer Research · 2011 · 189 citations
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer
Cancer Cell · 2016 · 166 citations
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
Nature Medicine · 2020 · 147 citations

Maria Baer
44 papers
Ashkan Emadi
30 papers
Firas El Chaer
12 papers
RK
Rami Komrokji
12 papers
ZS
Zeba Singh
12 papers
AL
Alan List
11 papers
Alice Mims
11 papers
Brian Druker
11 papers
ES
Eytan Stein
11 papers
Gary Schiller
11 papers
JB
John Byrd
11 papers
Rebecca Olin
11 papers

Grants

University of Maryland Greenebaum Cancer Centersupport Grant
National Cancer Institute · P30
Project lead · $627.4K · University of Maryland Baltimore
2008–2027

Clinical trials

Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL
Principal investigator · Completed · Phase 2
University of Maryland, Baltimore
2021–2025
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
Principal investigator · Completed · Phase 1
University of Maryland, Baltimore
2021–2025
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
Principal investigator · Recruiting · Phase 2
University of Maryland, Baltimore
2019–2028
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2025–2028